Lonza Group AG (LZAGF)
USD 588.7
(0.0%)
USD 588.7
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.81 Billion CHF | -25.51% |
| 2022 | 2.43 Billion CHF | 15.55% |
| 2021 | 2.11 Billion CHF | 14.18% |
| 2020 | 1.84 Billion CHF | -18.05% |
| 2019 | 2.25 Billion CHF | 7.74% |
| 2018 | 2.09 Billion CHF | 14.5% |
| 2017 | 1.82 Billion CHF | 30.48% |
| 2016 | 1.4 Billion CHF | 27.48% |
| 2015 | 1.09 Billion CHF | 2.33% |
| 2014 | 1.07 Billion CHF | 30.02% |
| 2013 | 826 Million CHF | -17.81% |
| 2012 | 1 Billion CHF | 43.57% |
| 2011 | 700 Million CHF | -1.55% |
| 2010 | 711 Million CHF | 30.46% |
| 2009 | 545 Million CHF | -35.04% |
| 2008 | 839 Million CHF | 3.58% |
| 2007 | 810 Million CHF | 43.62% |
| 2006 | 564 Million CHF | 0.53% |
| 2005 | 561 Million CHF | 20.39% |
| 2004 | 466 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 558 Million CHF | 0.0% |
| 2024 Q1 | 558 Million CHF | -33.57% |
| 2023 Q2 | 1.1 Billion CHF | 100.0% |
| 2023 Q1 | 554 Million CHF | -55.39% |
| 2023 Q3 | 647.5 Million CHF | -41.56% |
| 2023 FY | 1.81 Billion CHF | -25.51% |
| 2023 Q4 | 840 Million CHF | 29.73% |
| 2022 Q3 | 621 Million CHF | -48.08% |
| 2022 Q4 | 1.24 Billion CHF | 100.0% |
| 2022 FY | 2.43 Billion CHF | 15.55% |
| 2022 Q1 | 598 Million CHF | -43.96% |
| 2022 Q2 | 1.19 Billion CHF | 100.0% |
| 2021 Q4 | 1.06 Billion CHF | 100.0% |
| 2021 Q3 | 533.5 Million CHF | -48.85% |
| 2021 Q2 | 1.04 Billion CHF | 100.0% |
| 2021 Q1 | 521.5 Million CHF | -16.56% |
| 2021 FY | 2.11 Billion CHF | 14.18% |
| 2020 Q3 | 437 Million CHF | -64.27% |
| 2020 FY | 1.84 Billion CHF | -18.05% |
| 2020 Q4 | 625 Million CHF | 43.02% |
| 2020 Q1 | 487 Million CHF | -56.01% |
| 2020 Q2 | 1.22 Billion CHF | 151.13% |
| 2019 Q3 | 553.5 Million CHF | -3.57% |
| 2019 FY | 2.25 Billion CHF | 7.74% |
| 2019 Q4 | 1.1 Billion CHF | 100.0% |
| 2019 Q1 | 574 Million CHF | 6.89% |
| 2019 Q2 | 574 Million CHF | 0.0% |
| 2018 FY | 2.09 Billion CHF | 14.5% |
| 2018 Q3 | 537 Million CHF | -2.81% |
| 2018 Q2 | 552.5 Million CHF | 0.0% |
| 2018 Q1 | 552.5 Million CHF | 50.14% |
| 2018 Q4 | 537 Million CHF | 0.0% |
| 2017 FY | 1.82 Billion CHF | 30.48% |
| 2017 Q2 | 438 Million CHF | 0.0% |
| 2017 Q1 | 438 Million CHF | 16.18% |
| 2017 Q3 | 534 Million CHF | 21.92% |
| 2017 Q4 | 368 Million CHF | -31.09% |
| 2016 FY | 1.4 Billion CHF | 27.48% |
| 2016 Q2 | 350.5 Million CHF | 0.0% |
| 2016 Q1 | 350.5 Million CHF | 10.57% |
| 2016 Q4 | 377 Million CHF | 0.0% |
| 2016 Q3 | 377 Million CHF | 7.56% |
| 2015 Q2 | 263 Million CHF | 0.0% |
| 2015 FY | 1.09 Billion CHF | 2.33% |
| 2015 Q3 | 317 Million CHF | 20.53% |
| 2015 Q1 | 263 Million CHF | -2.95% |
| 2015 Q4 | 317 Million CHF | 0.0% |
| 2014 Q2 | 273.5 Million CHF | 0.0% |
| 2014 Q1 | 273.5 Million CHF | 15.64% |
| 2014 FY | 1.07 Billion CHF | 30.02% |
| 2014 Q4 | 271 Million CHF | 0.0% |
| 2014 Q3 | 271 Million CHF | -0.91% |
| 2013 Q3 | 236.5 Million CHF | -1.87% |
| 2013 FY | 826 Million CHF | -17.81% |
| 2013 Q1 | 241 Million CHF | 0.0% |
| 2013 Q4 | 236.5 Million CHF | 0.0% |
| 2013 Q2 | 241 Million CHF | 0.0% |
| 2012 FY | 1 Billion CHF | 43.57% |
| 2011 FY | 700 Million CHF | -1.55% |
| 2010 FY | 711 Million CHF | 30.46% |
| 2009 FY | 545 Million CHF | -35.04% |
| 2008 FY | 839 Million CHF | 3.58% |
| 2007 FY | 810 Million CHF | 43.62% |
| 2006 FY | 564 Million CHF | 0.53% |
| 2005 FY | 561 Million CHF | 20.39% |
| 2004 FY | 466 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | 941032.642% |
| Arrayit Corporation | 2.57 Million USD | -70422.683% |
| Atlantic International Corp. | -154.23 Thousand USD | 1177531.695% |
| Biocept, Inc. | -2.58 Million USD | 70433.075% |
| Bioqual, Inc. | 7.42 Million USD | -24344.306% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 276 Thousand USD | -657871.014% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 73.056% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | -101121.458% |
| iMD Companies, Inc. | -23.63 Thousand USD | 7682970.077% |
| IDenta Corp. | 662.97 Thousand USD | -273816.814% |
| Interpace Biosciences, Inc. | 23.04 Million USD | -7780.918% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | -2340981.074% |
| InVitro International | 635.98 Thousand USD | -285441.326% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | -27570.273% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | -166096.265% |
| NovelStem International Corp. | 12 Thousand USD | -15133233.333% |
| Optigenex Inc. | -102.96 Thousand USD | 1763788.985% |
| PharmChem, Inc. | 3.9 Million USD | -46411.914% |
| Proteome Sciences plc | 2.09 Million USD | -86515.146% |
| Response Genetics, Inc | 3.94 Million USD | -45967.986% |
| Rennova Health, Inc. | 6.26 Million USD | -28871.399% |
| RushNet, Inc. | 1.1 Million USD | -164301.171% |
| ScreenPro Security Inc. | 856.57 Thousand USD | -211907.369% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 449886.624% |
| Todos Medical Ltd. | 4.31 Million USD | -42034.571% |